Drug General Information |
Drug ID |
D00BSR
|
Former ID |
DIB004184
|
Drug Name |
JCAR017
|
Indication |
Leukemia [ICD9: 208.9; ICD10:C90-C95]
|
Phase 1/2 |
[1]
|
Company |
Juno therapeutics
|
Target and Pathway |
Target(s) |
B-lymphocyte antigen CD19 |
Target Info |
Modulator |
[2]
|
KEGG Pathway
|
PI3K-Akt signaling pathway
|
Hematopoietic cell lineage
|
B cell receptor signaling pathway
|
Epstein-Barr virus infection
|
Primary immunodeficiency
|
NetPath Pathway
|
IL-7 Signaling Pathway
|
PANTHER Pathway
|
B cell activation
|
Pathway Interaction Database
|
BCR signaling pathway
|
Reactome
|
PIP3 activates AKT signaling
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
WikiPathways
|
Human Complement System
|
Signaling by the B Cell Receptor (BCR)
|
PIP3 activates AKT signaling
|
B Cell Receptor Signaling Pathway
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
References |
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041076) |
---|
REF 2 | Clinical pipeline report, company report or official report of JUNO Therapeutics. |